Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients.
Zesheng AnXian ZhouYanfeng LiJane JaquithKathleen McCarthy-FruinJennifer SlettenKenneth J WarringtonCornelia WeyandCynthia S CrowsonSaranya ChumsriKeith L KnutsonGabriel Figueroa-ParraAlain Sanchez-RodriguezUma ThanarajasingamAlí Duarte-GarcíaHu ZengPublished in: medRxiv : the preprint server for health sciences (2023)
Patients with rheumatic diseases mount robust humoral immunity towards 3 doses of COVID-19 mRNA vaccines.Disease activity and biomarkers remain stable following 3 doses of COVID-19 mRNA vaccines.
Keyphrases
- coronavirus disease
- sars cov
- disease activity
- immune response
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- rheumatoid arthritis patients
- chronic kidney disease
- peritoneal dialysis
- juvenile idiopathic arthritis
- respiratory syndrome coronavirus
- prognostic factors
- dendritic cells